Scinai Immunotherapeutics Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The firm's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
Scinai Immunotherapeutics Ltd의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Scinai Immunotherapeutics Ltd 주요 수익원은 Time Charters이며, 최신 수익 발표에서 수익은 666,715,000입니다. 지역별로는 United States이 Scinai Immunotherapeutics Ltd의 주요 시장이며, 수익은 666,715,000입니다.
Scinai Immunotherapeutics Ltd은 수익성이 있나요?
예, 최신 재무제표에 따르면 Scinai Immunotherapeutics Ltd의 순이익은 $4입니다.
Scinai Immunotherapeutics Ltd에 부채가 있나요?
예, Scinai Immunotherapeutics Ltd의 부채는 3입니다.
Scinai Immunotherapeutics Ltd의 발행 주식은 몇 주인가요?
Scinai Immunotherapeutics Ltd의 총 발행 주식은 3,411.98주입니다.